ERGO Ergomed Plc

TIDMERGO

RNS Number : 6936G

Ergomed plc

17 November 2022

PRESS RELEASE

Ergomed Strengthens Executive Management Team

Michael Spiteri moves from Board to take up Executive Role as Chief Transformation and Technology Officer

Jonathan Curtain joins as Deputy CFO from ICON plc

Guildford, UK - 17 November 2022: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, today announces it has further strengthened its Executive Management Team with two significant senior appointments.

In line with the continued strengthening of our management team and our commitment to maximising the potential of technology across the business, Michael Spiteri has been appointed as Chief Transformation and Technology Officer ("CTTO"). As a result of the appointment, Michael has stepped down as a Non-Executive Director with immediate effect.

Michael has over 30 years' experience working in information technology and digital transformation with companies including Santander, Elixirr Partners, PwC, Accenture and IBM. He was previously Global Head of Insurance Transformation and Innovation, HSBC Life and Partnerships at HSBC. Michael specialises in helping organisations implement technology that transforms their business and operating models and, since joining Ergomed's Board of Directors in 2018, has helped Ergomed develop its capabilities across digital, automation and machine learning.

In addition, Jonathan Curtain has been appointed as Deputy Chief Financial Officer. Jonathan has extensive life sciences industry experience, having spent 13 years with ICON plc, a leading global CRO business listed on the NASDAQ with a market capitalization of $16 billion. Most recently, he was the Senior Vice President of Corporate and Commercial Finance, where he had a broad range of responsibilities including financial reporting, acquisitions and post-acquisition integration, debt and equity fundraising, treasury and overall financial management. During his time with ICON, he has also led the Investor Relations function and played a key role in transactions worth over $13.5 billion including most recently the $12 billion acquisition by ICON of PRA Health Sciences Inc. Jonathan has over 20 years' experience as a Chartered Account after receiving his ACA qualification at KPMG.

Dr. Miroslav Reljanović, Executive Chairman of Ergomed, commented: "I am excited to be announcing these two appointments to further strengthen our Executive Management Team.

Since joining our Board in 2018, Michael Spiteri's strategic insight has been extremely valuable to us as we have developed our strategy of digital transformation across the business. I am excited by Michael joining the Executive Management Team as CTTO to utilise his years of technology and transformation experience, which over time will become central to Ergomed's continued transformation and growth. His appointment demonstrates Ergomed's continued focus on becoming a leader in the application of digital technology in the pharmaceutical services industry, and I look forward to working more closely with him moving forward.

"I also welcome Jonathan Curtain to Ergomed. He has deep CRO industry experience from his 13 years with ICON and I believe his close involvement in ICON's significant growth, strategic M&A and post-acquisition integration will allow him to strengthen Ergomed's ability to deliver further success and strategic development internationally."

Michael Spiteri, CTTO, commented : "Technology has the potential to revolutionise clinical trials and the pharmacovigilance market and has become particularly relevant in the wake of the COVID-19 pandemic. Having worked closely with the Board as a Non-Executive Director for four years, I have seen first-hand the Company's success in developing and investing in technology to further enhance its service offerings. With this focus, I firmly believe that Ergomed is well placed to continue to develop a leading digital technology offering to drive efficiency and accuracy across the business for the benefit of our customers and, ultimately, patients."

Jonathan Curtain, Deputy CFO, said: "I am delighted to be joining Ergomed at this exciting time in the Company's development. I believe Ergomed is exceptionally strongly positioned to continue its growth and expansion and I look forward to working with the Executive Management Team and Board to continue on that trajectory through strong organic growth augmented by highly strategic acquisitions."

ENDS

Enquiries:

 
 Ergomed plc                                                  Tel: +44 (0) 1483 402 
                                                                                975 
 Miroslav Reljanović (Executive 
  Chairman) 
 Richard Barfield (Chief Financial Officer) 
 Keith Byrne (Senior Vice-President, 
  Capital Markets & Strategy) 
 
 Numis (Nominated Adviser and Joint                            Tel: +44 (0) 20 7260 
  Broker)                                                                      1000 
 Freddie Barnfield / Euan Brown (Nominated 
  Adviser) 
 James Black (Broker) 
 
  Peel Hunt LLP (Joint Broker)                                 Tel: +44 (0) 20 7418 
  James Steel / Dr Christopher Golden                                          8900 
 
 Consilium Strategic Communications                            Tel: +44 (0) 20 3709 
  - for UK enquiries                                                           5700 
 Chris Gardner / Matthew Neal / Angela                  ergomed@consilium-comms.com 
  Gray 
 
 
 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCDBBDBDUBDGDL

(END) Dow Jones Newswires

November 17, 2022 02:00 ET (07:00 GMT)

Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024